Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1
Hepatitis C, Chronic
Ledipasvir and sofosbuvir for 12 weeks provided high rates of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4. (Funded by Gilead Sciences; ION-4 ClinicalTrials.gov number, NCT02073656.).